Article Details

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program

Retrieved on: 2021-07-01 21:00:00

Tags for this article:

Click the tags to see associated articles and topics

Selexis and KBI Biopharma Partner with Immatics to Advance T-Cell Bispecific Program. View article details on hiswai:

Excerpt

Selexis and KBI Biopharma will use integrated services to advance Immatics' TCR bispecifics drug development program to the IND stage. On June ...

Article found on: www.pharmtech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo